Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

A genome-wide association study of brain lesion distribution in multiple sclerosis.
Mitoxantrone for multiple sclerosis.
BRIEF-Health Canada approves Genzyme's Aubagio to treat relapsing remitting multiple sclerosis
Pharmacokinetic properties and metabolism of idebenone.
Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis.
Therapeutic class review, Neurological - multiple sclerosis dalfampridine (Ampyra(TM))
Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain.
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation.
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year.
Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Full-Term Pregnancy.
URMC rheumatologist presents data showing drug’s potential to ease arthritis symptoms
Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels.
Immunology 2014
Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.
Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
Integrated analysis of daclizumab HYP pharmacokinetics from three phase 1 studies
Role of the Blood-Brain Barrier in Multiple Sclerosis.
Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.
Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study.
Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.
Imaging robust microglial activation after lipopolysaccharide administration in humans with PET.
Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study.
Estimating Time to Disease Progression Comparing Transition Models and Survival Methods-An Analysis of Multiple Sclerosis Data.

Pages